
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New Orleans - Treating some types of psoriasis - severe, scalp, arthritic, "out of town," and others - can challenge the therapeutic acumen of dermatologists.






